Beauty Health Co (NASDAQ: SKIN) grants 746,681 RSUs to CSO and COO
The Beauty Health Co (NASDAQ: SKIN) reported that its CSO and COO, Sheri Lewis, received a grant of 746,681 restricted stock units (RSUs). These RSUs represent equity compensation and will vest in three equal installments over three years, contingent on continued service. Following this grant, Lewis beneficially owns 1,609,524 shares of Class A Common Stock.
Beauty Health Co (NASDAQ: SKIN) CEO granted 2.65M RSUs in new stock award
The CEO of The Beauty Health Co (NASDAQ: SKIN), Pedro Bruno Ferreira Malha, has been granted 2.65 million Restricted Stock Units (RSUs) as part of a new stock award. This equity compensation vests in three equal annual installments beginning March 20, 2026, contingent on continued service. Following this grant, Malha beneficially owns 4,845,251 shares of Class A Common Stock.
Beauty Health Co (NASDAQ: SKIN) CRO receives 746,681 restricted stock units
The Beauty Health Co (NASDAQ: SKIN) Chief Revenue Officer, Ronald Menezes, was granted 746,681 restricted stock units (RSUs) as part of his compensation. These RSUs will vest in three equal annual installments starting March 20, 2026, contingent on his continued employment. Following this grant, Menezes' direct ownership in Beauty Health Co totals 1,759,915 shares of Class A Common Stock.
Beauty Health Co (NASDAQ: SKIN) CFO awarded 746,681 restricted stock units
Michael P. Monahan, CFO of Beauty Health Co (NASDAQ: SKIN), has been granted 746,681 restricted stock units (RSUs) as part of a compensation package. These RSUs will vest in three equal annual installments beginning March 20, 2026, contingent on his continued employment. Following this award, Monahan directly holds 2,014,413 shares or share-equivalent units, as detailed in a recent SEC Form 4 filing.
Mirabella Financial Services LLP Buys 2,734,728 Shares of The Beauty Health Company $SKIN
Mirabella Financial Services LLP increased its stake in The Beauty Health Company (NASDAQ:SKIN) by 21.3%, purchasing over 2.7 million shares in the third quarter, making SKIN its sixth-largest holding. Other institutional investors like Woodline Partners LP and Bank of America Corp DE also significantly boosted their positions. Despite recent earnings beating estimates, analysts maintain a consensus "Hold" rating with an average target price of $2.42 due to high leverage and a negative price-to-earnings ratio.
Mirabella Financial Services LLP Raises Stock Position in The Beauty Health Company $SKIN
Mirabella Financial Services LLP significantly increased its stake in The Beauty Health Company (NASDAQ:SKIN) by 21.3% in Q3, now owning 12.23% of the company, valued at approximately $31.0 million. Despite this increase, the company remains unprofitable with high leverage and carries an average analyst rating of "Reduce" with a target price of $2.42. The Beauty Health Company is trading around $1.20, with a market capitalization of $152 million, and a beta of 1.20, while institutional investors and hedge funds hold 93.26% of its stock.
The Beauty Health Company (NASDAQ:SKIN) Receives Consensus Rating of "Reduce" from Brokerages
The Beauty Health Company (NASDAQ:SKIN) has received a consensus "Reduce" rating from eight brokerages, with an average 12-month target price of $2.42. The stock is currently trading around $1.20, with analysts forecasting a negative EPS of approximately -$0.25 for the current year, despite beating Q4 estimates. Institutional investors have been adjusting their positions in the company, which specializes in device-based and product-based offerings in the beauty and wellness sector.
Beauty Health (NASDAQ:SKIN) Price Target Lowered to $1.50 at TD Cowen
TD Cowen has lowered its price target for Beauty Health (NASDAQ:SKIN) from $1.65 to $1.50, while maintaining a "hold" rating, suggesting a potential 14.5% upside from the current share price. The company currently trades around $1.31 with a market cap of $167 million and analysts have an average "Reduce" rating with a target price of $2.42. Despite high leverage and negative EPS, Beauty Health's recent quarterly revenue of $82.37 million exceeded estimates.
Beauty Health's (SKIN) Hold Rating Reiterated at Canaccord Genuity Group
Canaccord Genuity Group has reiterated a "hold" rating on Beauty Health (SKIN) with a $1.50 price target, suggesting a potential 19.5% upside. This comes after the beauty company beat Q4 revenue and EPS estimates but provided Q1 guidance slightly below consensus and continues to face challenges with profitability and leveraging metrics. Analyst sentiment for Beauty Health remains mixed, with a MarketBeat consensus rating of "Reduce" and a target price of $2.45.
Beauty Health (SKIN) Projected to Post Quarterly Earnings on Thursday
Beauty Health (NASDAQ:SKIN) is expected to announce its Q4 2025 earnings after market close on Thursday, March 12, 2026, with analysts projecting an EPS of ($0.07) and revenue of approximately $78.07 million. The company's stock currently holds a "Reduce" rating from analysts with an average price target of $2.40. Institutional investors own a significant portion of the stock, which has a market cap of $140.25 million, strong liquidity, but a high debt-to-equity ratio.
The Beauty Health Company - Class A Common Stock (NQ: SKIN)
This article provides recent news headlines and press releases related to The Beauty Health Company (Nasdaq: SKIN). It lists various announcements from 2022 and 2023, including product launches, financial reporting dates, strategic partnerships, and leadership appointments. The company's stock information, showing a gain of 7.22% at 4:00 PM EST on February 27, 2026, is also presented.
EBIT per share of Beauty Health Company Class A – GETTEX:V7A0
The article focuses on the EBIT per share for Beauty Health Company Class A, traded under the symbol V7A0 on Gettex. It appears to be a financial data page from TradingView, providing an overview of the company's financial performance metrics. The content indicates that market data is provided by ICE Data Services, and reference data by FactSet.
The Beauty Health Company (NASDAQ:SKIN) Receives Average Rating of "Reduce" from Analysts
The Beauty Health Company (NASDAQ:SKIN) has received an average analyst rating of "Reduce" based on reports from seven research firms, with a consensus 12-month price target of $2.40. The company's stock is currently trading around $1.53, and it recently reported a quarterly EPS of ($0.09), missing estimates. Institutional investors collectively own approximately 93.26% of the shares, with several significant holders increasing their positions in the last quarter.
Beauty Health (NASDAQ:SKIN) Stock Rating Lowered by Zacks Research
Zacks Research has downgraded Beauty Health (NASDAQ:SKIN) from a "hold" to a "strong sell" rating. This comes after the company missed its quarterly EPS estimates and shows negative margins, negative return on equity, and a high debt-to-equity ratio. Analysts currently have a "Reduce" consensus rating for the stock with a target price of $2.40.
Beauty Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of The Beauty Health Company - SKIN
Kahn Swick & Foti, LLC (KSF) has launched an investigation into The Beauty Health Company (SKIN) and its officers and directors following a significant drop in financial performance and the departure of its CEO. The investigation centers on potential breaches of fiduciary duty and violations of state or federal laws, spurred by disclosures of lower-than-expected U.S. revenue, substantial restructuring charges, and a revised financial outlook. KSF is inviting long-term shareholders with relevant information to assist in their ongoing inquiry.
The Beauty Health Company (NASDAQ:SKIN) Receives Consensus Recommendation of "Hold" from Brokerages
The Beauty Health Company (NASDAQ:SKIN) has received a consensus "Hold" recommendation from seven brokerages, with an average 12-month target price of $2.81. Recent financial results showed a quarterly EPS miss at -$0.09 and a revenue beat at $70.66M, while analysts expect a full-year EPS around -$0.25. Institutional investors hold a significant portion of the company's stock, which recently traded at $1.39 with a market cap of $177.2 million.
Beauty Health (NASDAQ:SKIN) Shares Down 1.4% - Here's Why
Beauty Health (NASDAQ:SKIN) shares fell 1.4% on Monday to $1.44, with trading volume down 37% from its average. The company reported a Q4 EPS of ($0.09), missing consensus by $0.01, though revenue beat estimates. Wall Street analysts maintain a "Hold" rating with an average target of $2.81, but the company faces high leverage and remains unprofitable.
HALPER SADEH LLC ENCOURAGES THE BEAUTY HEALTH COMPANY SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of The Beauty Health Company (NASDAQ: SKIN) breached their fiduciary duties to shareholders. The firm encourages current long-term shareholders to contact them to discuss potential legal rights and options, including corporate governance reforms, return of funds, or financial incentive awards. Halper Sadeh LLC represents investors globally and aims to improve company policies and oversight for enhanced shareholder value.
China’s Cosmetics and Personal Care Market: Key Trends and Business Outlook
China's cosmetics and personal care market is projected to reach US$78 billion by 2025, becoming the world's second-largest market and a key driver of growth in Asia. The article highlights the dominance of e-commerce, the increasing demand for premium, natural, and AI-driven beauty products, and the evolving regulatory landscape. It also provides insights for foreign brands on navigating the competitive market, emphasizing the importance of deep brand evaluation, focused targeting, diversified distribution, and leveraging KOLs/KOCs.
Halper Sadeh LLC Encourages The Beauty Health Company Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of The Beauty Health Company (NASDAQ: SKIN) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of Beauty Health to contact them to discuss their legal rights and options, which may include seeking corporate governance reforms or the return of funds to the company. Halper Sadeh LLC emphasizes that shareholder involvement can enhance shareholder value by improving company policies and oversight.
The Beauty Health Company (NASDAQ:SKIN) Receives Average Rating of "Hold" from Analysts
The Beauty Health Company (NASDAQ:SKIN) has received an average "Hold" rating from analysts, with a consensus one-year price target of $2.8125. The company recently reported better-than-expected quarterly earnings and revenue, but institutional investors have shown mixed activity in the stock.
Hydrafacial Owner Appoints New CEO
The Beauty Health Company, owner of Hydrafacial, has appointed Pedro Malha, previously of Abbott Laboratories, as its new chief executive, effective October 1. He succeeds Marla Beck, who will transition to an advisory role. Malha brings extensive experience in healthcare and medical devices to the company.
ETFs Investing in Beauty Health Company Class A Stocks
This article lists several ETFs that invest in The Beauty Health Company Class A stocks (SKIN). It provides details for each ETF including market value, weight of SKIN stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The ETFs mentioned include Vanguard Consumer Staples ETF (VDC), iShares Russell 2000 Growth Fund (IWO), iShares Microcap ETF (IWC), Janus Henderson Small Cap Growth Alpha ETF (JSML), and Vanguard Russell 2000 Growth ETF (VTWG).
The Vogue Business 2025 100 Innovators: Beauty Disruptors
This article highlights the "Beauty Disruptors" section of the Vogue Business 2025 100 Innovators list, showcasing individuals who are reshaping the beauty industry through innovation, technology, and conscious practices. It profiles 18 leaders including CEOs, founders, perfumiers, and marketers who are addressing new consumer demands, leveraging AI and digital platforms, and focusing on sustainability and inclusivity. Their contributions range from transforming embattled brands and creating virtual cosmetics to pioneering biotech ingredients and redefining digital retail strategies.
How to Innovate in Beauty in 2025
In 2025, beauty innovation is shifting focus from consumer-facing AR/VR experiences to new product development and personalized services with clear ROI. Brands like Nars, Shiseido, and Clinique lead with evergreen innovations like skin diagnostics and color matching, while La Mer and The Ordinary show significant growth by integrating education and efficacy into their AR marketing. Personalization remains a key investment area, evolving to include wellness and leveraging data, though personalized product formulations are still limited due to cost and consumer willingness to pay.
Many beauty products have toxic ingredients. Newly proposed bills could change that
Democratic lawmakers have reintroduced the "Safer Beauty Bill Package" to address the lack of regulation in the cosmetics industry, aiming to ban toxic ingredients and protect vulnerable populations. This legislative effort seeks to close gaps left by previous laws and align U.S. cosmetic safety standards with those in other regions like the European Union. The proposed bills target specific chemical bans, mandate ingredient transparency, require health risk disclosures, and fund research for safer alternatives, particularly for products marketed to women of color and salon workers.
Beyond the Glow: Key Medical Spa Compliance Challenges and Legal Pitfalls
The medical spa industry is experiencing rapid growth, but this expansion brings complex legal and regulatory challenges. Owners and operators must navigate strict compliance with ownership requirements, licensing, advertising regulations, and risk management obligations, especially under California law. This article offers practical guidance to ensure patient safety, regulatory adherence, and long-term success in the medical spa sector.
Podcast - Navigating the Rapid Growth of the Med Spa Industry
This podcast episode discusses the rapid growth and future of the medical spa (med spa) industry, highlighting its market value, growth drivers like increased consumer demand for non-invasive procedures, and the appeal of the cash-pay model for investors. It also covers regulatory considerations, the industry's fragmentation ripe for consolidation, and challenges such as provider retention and navigating diverse state regulations. The speakers emphasize strategic planning for med spa owners and investors to capitalize on this expanding market.
The beauty boom and beyond: Can the industry maintain its growth?
The global beauty industry grew by 10 percent in 2023 to $446 billion, largely driven by price increases rather than volume. While inflation is cooling, the industry is expected to reach $590 billion by 2028 with a 6 percent annual growth rate, driven by regional differences and continued innovation in categories like skincare and fragrance. The article highlights the importance of product differentiation, agility, and a balanced approach to online and in-store experiences for future sustainable growth.
Marla Beck named CEO of BeautyHealth
Marla Beck, founder of Bluemercury, has been appointed as the permanent CEO of BeautyHealth after serving as interim chief since November. Her appointment comes as BeautyHealth reported a 1.3% year-over-year decline in fourth-quarter net sales and a net loss of $100.1 million for the full year. Beck faces challenges including product issues with Syndeo devices, which led to a securities class action lawsuit and a $63.1 million restructuring charge.
SHAREHOLDER ALERT: Levi & Korsinsky Notifies The Beauty Health Company(SKIN) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP has notified investors of The Beauty Health Company (SKIN) about a class action lawsuit filed against the company. The lawsuit alleges securities fraud between May 10, 2022, and November 13, 2023, due to issues with the Syndeo devices leading to significant costs and inventory write-downs. Investors who suffered losses during this period have until January 16, 2024, to request to be appointed as lead plaintiff.
Beauty Health Company (SKIN) Faces Investor Lawsuit for Allegedly Concealing Syndeo’s “Frequent Treatment Interruptions” – Hagens Berman
Hagens Berman is urging investors of The Beauty Health Company (SKIN) who suffered substantial losses to contact their firm before the January 16th deadline for a securities fraud class action. The lawsuit alleges that Beauty Health concealed frequent treatment interruptions with its Syndeo devices, leading to significant financial repercussions and a sharp decline in stock value. This legal action follows a dismal Q3 2023 disclosure, which revealed lower-than-expected U.S. revenue, restructuring charges, and a cut in FY 2023 guidance, leading to the CEO's departure.
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders
The Gross Law Firm has issued a shareholder alert regarding a class action lawsuit against The Beauty Health Company (NASDAQ: SKIN). Shareholders who bought shares between May 10, 2022, and November 13, 2023, are encouraged to contact the firm, with a lead plaintiff deadline of January 16, 2024. The lawsuit alleges that the company made false or misleading statements concerning issues with its Syndeo devices, leading to significant costs and inventory write-downs.
BeautyHealth to Acquire SkinStylus®, FDA-Cleared Microneedling Device
The Beauty Health Company, known for its Hydrafacial brand, announced the acquisition of SkinStylus®, an FDA-cleared microneedling device. This strategic move aims to expand BeautyHealth's portfolio and strengthen its position as a leading beauty, health, and wellness platform, with microneedling being highly complementary to Hydrafacial treatments. The company expects the acquisition to contribute to its growth starting in 2024 and beyond.
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 16, 2024 in Beauty Health Lawsuit – SKIN
Levi & Korsinsky LLP reminds shareholders of The Beauty Health Company (NASDAQ:SKIN) about a lead plaintiff deadline of January 16, 2024, in a securities class action lawsuit. The lawsuit alleges that Beauty Health made false statements regarding issues with its Syndeo devices, leading to significant costs and inventory write-downs. Shareholders who suffered losses between May 10, 2022, and November 13, 2023, are encouraged to seek information about their rights.
SKIN INVESTOR NOTICE: The Beauty Health Company Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against The Beauty Health Company (NASDAQ: SKIN) on behalf of investors who purchased securities between May 10, 2022, and November 13, 2023. The lawsuit alleges that Beauty Health concealed significant issues with its Syndeo devices, leading to substantial financial write-downs and a negative impact on profitability, resulting in a dramatic drop in stock price and executive departures. Investors with significant losses have until January 16, 2024, to seek appointment as lead plaintiff.
SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 16, 2024 to Discuss Your Rights - SKIN
Levi & Korsinsky LLP has issued a shareholder alert for investors of The Beauty Health Company (NASDAQ: SKIN) who suffered losses between May 10, 2022, and November 13, 2023. A class action lawsuit alleges that the company made false statements regarding issues with its Syndeo devices, leading to significant costs and inventory write-downs that negatively impacted profitability. Shareholders are encouraged to contact the law firm before January 16, 2024, to discuss their rights and potential recovery.
The BeautyHealth Company Announces a Leadership Shakeup
The BeautyHealth Company announced that its president and chief executive, Andrew Stanleick, will be stepping down on November 19, with Marla Beck serving as interim CEO. This leadership change follows a third-quarter earnings report that showed a net income loss of $73.8 million, primarily attributed to issues with its Syndeo device, and an 86.2 percent drop in its stock price over 24 months. Stanleick had joined the company in January 2022.
Brands on Fire: BeautyHealth CMO Dishes on Hydrafacial’s Marketing Evolution
BeautyHealth CMO Amy Juaristi details Hydrafacial's marketing evolution from a B2B focus to a hybrid B2C model, emphasizing direct consumer engagement while supporting providers. She highlights successful initiatives like the GLOWvolution pop-up tour and increased influencer marketing investments, noting the shift in beauty consumer behavior towards professional, results-driven treatments. Juaristi also addresses the challenges of marketing in a broad beauty landscape where consumers prioritize efficacy and readily discuss cosmetic procedures.
Unpacking the Fine Print of the Not So Pretty Documentary Series
This article analyzes the HBO documentary series "Not So Pretty," which investigates the lack of regulation and potential dangers in the cosmetics industry across various product categories like makeup, hair care, nail care, and skincare. It delves into specific issues raised in each episode, such as asbestos in makeup and health problems faced by nail salon workers, and examines the role of the FDA, brand accountability, and differing regulatory standards between the US and the EU. Experts provide counterarguments and nuance, highlighting the complexity of ingredient safety, the impact of "clean beauty" marketing, and the need for comprehensive legislative change and industry-wide transparency.
The Beauty Health Company Acquires Four International Distributors for Hydrafacial
The Beauty Health Company, parent of The HydraFacial Company, is expanding its global presence by acquiring four international third-party distributors in Germany, Australia, France, and Mexico. The acquisitions, totaling approximately $35 million, are expected to be immediately accretive to earnings and solidify the company's direct presence in these key markets. This move aligns with BeautyHealth's strategy to foster direct engagement with providers and consumers globally, enhancing brand awareness and leveraging successful past acquisitions.
HydraFacial and Vesper Healthcare Close $1.1B Deal
Vesper Healthcare Acquisition and The HydraFacial Company have completed their business combination, forming The Beauty Health Company with a pro forma enterprise value of $1.1 billion. The merger was approved by Vesper Healthcare's stockholders, and the new company's shares will trade on Nasdaq under the ticker SKIN starting May 6th. Linden Capital Partners will remain the largest shareholder in BeautyHealth.
